Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 8/20 | 0.54 |
| ▸ | FAAH | O00519 | 3/20 | 0.54 |
| ▸ | DRD2 | P14416 | 14/20 | 0.53 |
| ▸ | HTR2A | P28223 | 9/20 | 0.53 |
| ▸ | HTR1A | P08908 | 5/20 | 0.53 |
| ▸ | DRD4 | P21917 | 6/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5444161 | 0.94 | ADRA1D (0.51) | DRD3FAAHDRD2HTR2AHTR1A | |
| SCHEMBL14410944 | 0.84 | CNR2 (0.48) | — | |
| SCHEMBL14410921 | 0.84 | L3MBTL1 (0.54) | DRD3DRD2HTR1ASIGMAR1 | |
| SCHEMBL5451102 | 0.83 | CNR2 (0.54) | DRD3DRD2DRD4 | |
| SCHEMBL5453731 | 0.83 | CNR2 (0.48) | DRD3HTR2A | |
| SCHEMBL5444412 | 0.82 | CNR2 (0.51) | DRD2DRD4 | |
| SCHEMBL14410865 | 0.82 | CNR2 (0.46) | — | |
| SCHEMBL14410851 | 0.81 | CNR2 (0.46) | — | |
| SCHEMBL14464412 | 0.80 | CNR2 (0.46) | HTR1ASLC6A4 | |
| SCHEMBL5461540 | 0.80 | CNR2 (0.46) | DRD3DRD2HTR2AHTR1ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | DRD3 2993/4885FAAH 406/4885DRD2 2688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.